<DOC>
	<DOCNO>NCT00034489</DOCNO>
	<brief_summary>This study explore well combination LY231514 Gemcitabine work together patient breast cancer spread beyond location original tumor . Patients must previously receive treatment anthracycline taxane chemotherapy drug .</brief_summary>
	<brief_title>A Phase II Study Combination MTA ( LY231514 ) Gemcitabine Patients With Metastatic Breast Cancer .</brief_title>
	<detailed_description>Gemcitabine give vein 30 minute day 1 &amp; 8 21-day cycle . LY231514 also give vein 10 minute day 8 , follow Gemcitabine injection . Vitamin supplementation oral folic acid injectable B12 initiate 7-10 day prior first dose LY231514 , continue throughout patient 's participation . Vitamin B12 administer approximately every 9 week first injection . Appropriate antiemetic medication give patient . Dexamethasone 4mg PO twice daily give 3 day per cycle , begin 1 day prior LY231514 dose . This give prevent lessen possibility rash .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>confirm diagnosis breast cancer measurable disease receive prior anthracycline taxane life expectancy &gt; 3 month acceptable lab result &gt; 3 prior regimen prior treatment protocol drug prior ( pelvic ) radiation active CNS metastasis inability take oral vitamin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>combination therapy</keyword>
	<keyword>Alimta</keyword>
</DOC>